TABLE 1.
Characteristics of the study subject population at study entry
| Characteristic | Placebo group | Tenofovir DF dose group
|
Total | |||
|---|---|---|---|---|---|---|
| 75 mg | 150 mg | 300 mg | 600 mg | |||
| No. of subjects | 11 | 12 | 8 | 8 | 10 | 49 |
| Sex (male/female) | 7/4 | 12/0 | 5/3 | 7/1 | 10/0 | 41/8 |
| Age (yrs)a | 37 (33–44) | 38.5 (32.5–42) | 38 (35–40.5) | 41 (33–46) | 42.5 (37–44) | 39 (34–44) |
| No. (%) Caucasian | 4 (50) | 5 (42) | 2 (25) | 5 (63) | 5 (50) | 21 (43) |
| No. (%) African-American | 7 (64) | 6 (50) | 4 (50) | 2 (25) | 4 (40) | 23 (47) |
| No. (%) Hispanic | 0 | 1 (8) | 2 (25) | 1 (13) | 0 (0) | 4 (8) |
| HIV-1 RNA level (log10 copies/ml)a | 4.53 (4.16–4.95) | 4.7 (4.23–5.01) | 4.5 (4.44–5.13) | 4.12 (3.91–4.55) | 4.64 (4.48–4.75) | 4.53 (4.2–4.92) |
| CD4 cell count (cells/mm3)a | 373 (259–444) | 388 (278–435) | 274 (253–466) | 375 (323–564) | 262 (185–289) | 330 (259–444) |
| No. (%) with prior antiretroviral use | 4 (36) | 8 (67) | 7 (88) | 4 (50) | 7 (70) | 30 (61) |
a
Median (values in parentheses are upper and lower boundaries of interquartile ranges).